Karuna Therapeutics, Inc. ((KRTX)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Study Overview: Karuna Therapeutics, Inc. is conducting a Phase 3 global, multicenter, open-label extension study titled A Phase 3 Global, Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer’s Disease. The primary objective is to evaluate the long-term safety and tolerability of KarXT in patients with Alzheimer’s-related psychosis, a significant concern given the growing prevalence of Alzheimer’s disease.
Intervention/Treatment: The study tests KarXT, an experimental drug combining Xanomeline and Trospium Chloride, intended to manage psychosis symptoms in Alzheimer’s patients.
Study Design: This interventional study follows a single-group assignment model with no masking, focusing primarily on treatment. Participants are those who have completed previous related studies, ensuring continuity in assessing KarXT’s effects.
Study Timeline: The study began on July 11, 2023, and is currently recruiting participants. The primary completion and estimated completion dates are yet to be updated, with the last update submitted on August 11, 2025. These dates are crucial for tracking progress and anticipating results.
Market Implications: The ongoing study could significantly impact Karuna Therapeutics’ stock performance, as positive results may enhance investor confidence and position KarXT favorably against competitors in the Alzheimer’s treatment market. The pharmaceutical industry closely watches such developments, given the high stakes in Alzheimer’s therapeutics.
The study is ongoing, with further details available on the ClinicalTrials portal.